ABMD - Abiomed, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
181.69
-7.53 (-3.98%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close189.22
Open189.30
Bid0.00 x 1100
Ask0.00 x 1200
Day's Range179.54 - 189.83
52 Week Range155.02 - 364.31
Volume730,523
Avg. Volume708,970
Market Cap8.2B
Beta (3Y Monthly)0.32
PE Ratio (TTM)37.93
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • These are the 20 best-performing stocks of the past decade, and some of them will surprise you
    MarketWatch

    These are the 20 best-performing stocks of the past decade, and some of them will surprise you

    DEEP DIVE As we approach the end of 2019, it’s time not only for year-end lists, but end-of-decade lists. U.S. stocks have had what can only be called an excellent decade. MarketWatch will feature a number of forward-looking articles building on the past decade’s action.

  • The stock market's biggest winners and losers of the past decade
    Yahoo Finance

    The stock market's biggest winners and losers of the past decade

    With the 2010s officially drawing to a close, Yahoo Finance took a look at some of the biggest S&P 500 winners and losers of the past decade based on price returns.

  • Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018​
    American City Business Journals

    Money in Medicine: These drug and device companies paid the most to D.C. doctors in 2018​

    The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.

  • Investopedia

    4 Big Name Stocks To Weigh Selling Now Before Losses Widen

    Macy's, 3M, Occidental and Abiomed are down sharply in 2019, and tax loss selling may send them plunging yet more.

  • Benzinga

    Cramer Weighs In On Biogen, Caterpillar And More

    Jim Cramer spoke on CNBC's "Mad Money Lightning Round" about Biogen Inc (NASDAQ: BIIB ). He is concerned about the stock because a Baird analyst expressed his skepticism about Biogen's Alzheimer's ...

  • Did You Miss Abiomed's (NASDAQ:ABMD) Whopping 426% Share Price Gain?
    Simply Wall St.

    Did You Miss Abiomed's (NASDAQ:ABMD) Whopping 426% Share Price Gain?

    Abiomed, Inc. (NASDAQ:ABMD) shareholders have seen the share price descend 11% over the month. But that does not...

  • These Medical Stocks Are Outperforming 95% Of All Stocks — Here's Why
    Investor's Business Daily

    These Medical Stocks Are Outperforming 95% Of All Stocks — Here's Why

    Medical technology companies are rising bullishly in 2019. The best-performing medical stocks tend to have high Composite Ratings, reflecting strong growth metrics vs. all other stocks.

  • Barrons.com

    The S&P 500 Notches Its 26th Record This Year Before Falling Back

    “Over the last couple of months, we’ve seen equity investors getting pulled in reluctantly to a rising market,” says Citi’s Tobias Levkovich.

  • 10 Best Stocks of the Past 10 Years
    Kiplinger

    10 Best Stocks of the Past 10 Years

    These companies powered through the past decade. Can they keep it up?

  • TEST Business Wire Releases

    Abiomed to Present at the 31st Annual Piper Jaffray Healthcare Conference

    Abiomed to Present at the 31st Annual Piper Jaffray Healthcare Conference

  • Barrons.com

    Stocks Are Going Nowhere as Hope for a China Trade Deal Wavers

    Worries flared that the U.S. and China won’t be able to reach a trade deal. Nvidia bounced back from its post-earnings drop at the end of last week.

  • TheStreet.com

    [video]Abiomed Shares Take Beating After Studies Question Heart Pump

    The stock plunges after new research unveiled at an American Heart Association meeting showed a higher risk of 'adverse events and costs' associated with the use of the Impella compared to the lower-tech, intra-aortic balloon often used.

  • Thomson Reuters StreetEvents

    Edited Transcript of ABMD earnings conference call or presentation 31-Oct-19 12:00pm GMT

    Q2 2020 Abiomed Inc Earnings Call

  • 3 Former Growth Stocks to Consider Buying Again
    InvestorPlace

    3 Former Growth Stocks to Consider Buying Again

    All stocks correct. It's also a fact that growth stocks come and go. But sometimes Wall Street's cautious dismissal of future prospects can lead to big-time profits. And right now Abiomed (NASDAQ:ABMD), Ulta Beauty Salon (NASDAQ:ULTA) and Baidu (ADR) (NASDAQ:BIDU) are three former dearly-held companies that maintain growth stock potential and bottoms ready for purchase.ABMD, ULTA and BIDU stock owners have all enjoyed better years than 2019. Shares of Abiomed are off roughly 33%. Ulta Salon has a blemish of 5% for its year-to-date performance. And Baidu is down by about 22% for the calendar year. But it's not the end of the road for these once dearly held growth stocks.The truth is most companies won't become the next Apple (NASDAQ:AAPL), Netflix (NASDAQ:NFLX) or Home Depot (NYSE:HD). But Wall Street also has a great record of overcompensating when the narrative turns to doom and gloom in growth stocks.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Medical Marijuana Stocks to Cure Your Portfolio I believe common but large corrections aided by Wall Street's willingness to flee the scene when there's a bump or two in the road are now setting up new opportunities for ABMD, ULTA and BIDU stock in 2020 and beyond. Let's examine what's happening in this diverse trio of former growth stocks who've endured big-time corrections and whose stories are poised for new chapters of growth off and on the price chart. Growth Stocks to Buy: Abiomed (ABMD)Abiomed is the first of our stocks to buy. The medical device maker and former staple within growth names pitched at Investor's Business Daily recently delivered a mixed, but decent and very well-received earnings report. And the story gets better for today's bullish investors. Away from the headlines, analysts are still projecting a five-year growth rate of 24% for the cardiac specialist. At the same time, with Wall Street having literally written off ABMD with a sizable correction in 2019, a bottom has now emerged on the price chart.ABMD Stock Strategy: With a confirmed monthly chart candlestick reversal pattern off its 10-year cycle, 62% retracement level and oversold stochastics crossover set-up turning higher, ABMD is a stock to buy today. I'd recommend setting a stop-loss beneath $190, which allows enough leeway off and on the price chart. To reduce exposure on a rally, a 50% retracement within the right side of a new bullish base in the range of $300 - $320 makes sense. Ulta (ULTA)Ulta Beauty is another former growth superstar hit by an inevitable correction made worse by failing to live up to Wall Street's overly high expectations. But don't think for a second the brick-and-mortar beauty retailer isn't still a growth stock or at least one well-positioned as a stock to buy.Sporting an estimated growth rate of over 10% for the next five years, a forward price multiple of 18 and share price that successfully tested its 10-year 38% Fibonacci level and five-year trendline support last month, ULTA has the right foundation as a stock to buy. * 7 Large-Cap Stocks to Give a Wide Berth ULTA Stock Strategy: My recommendation in this growth stock is to wait for a second price confirmation of the September high of $251.76. Also, the September pivot low of $224.66 is our line in the sand. The fact is, shares have backtracked and, while stochastics are oversold, the indicator hasn't yet put together a bullish crossover confirmation. Baidu (BIDU)Baidu is the last of our growth stocks to buy. The China-based search giant and diversified technology play touted as China's Alphabet (NASDAQ:GOOGL, (NASDAQ:GOOG) has lost roughly two-thirds of its value since mid-2018. Blame it on dashed expectations and even some scandal along the way. And you can.But as the dust has settled on shares, BIDU stock is showing sure signs of a comeback worth buying into. This week, the company reported stronger-than-expected results and Wall Street has been receptive to the report. To be clear, growth of days past isn't there at this point, but the stage for a turnaround in this market leader is certainly in progress.BIDU Stock Strategy: Technically, the reaction to Baidu's earnings has hoisted shares of this return-to-growth stock above a failed bear flag and three-month long consolidation just below its decade-plus 62% level. With stochastics backing a longer-term bottom, BIDU is a stock to buy. However, given a shorter-term overbought condition and expectations this turnaround will take some time to unfold, I'd recommend watching for an opportunity to buy Baidu on weakness, rather than momentum. Also, consider a stop-loss below $100.Disclosure: Investment accounts under Christopher Tyler's management do not currently own positions in securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional market insights and related musings, follow Chris on Twitter @Options_CAT and StockTwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Sell Before They Roll Over * 5 Beaten-Up Stocks to Buy That Could Be Saved By An Acquisition * 4 Startup Stocks Getting Smashed The post 3 Former Growth Stocks to Consider Buying Again appeared first on InvestorPlace.

  • What Is Abiomed's (NASDAQ:ABMD) P/E Ratio After Its Share Price Rocketed?
    Simply Wall St.

    What Is Abiomed's (NASDAQ:ABMD) P/E Ratio After Its Share Price Rocketed?

    Abiomed (NASDAQ:ABMD) shareholders are no doubt pleased to see that the share price has had a great month, posting a...

  • GuruFocus.com

    US Stocks Tumble Thursday

    Apache advances on financial results Continue reading...

  • Zacks

    Impressive Near-Term Outlook for Medical Instruments Industry

    Impressive Near-Term Outlook for Medical Instruments Industry

  • TheStreet.com

    Abiomed Shares Climb After Medical-Tech Provider Reiterates Earnings Guidance

    Full-year revenue at the provider of technology to support the heart's blood circulation is seen up 15% to 20%

  • ABIOMED (ABMD) Earnings Beat, Revenues Miss Estimates in Q2
    Zacks

    ABIOMED (ABMD) Earnings Beat, Revenues Miss Estimates in Q2

    Impella's solid show in Japan drives ABIOMED's (ABMD) fiscal second-quarter results.

  • Abiomed (ABMD) Q2 Earnings Top Estimates
    Zacks

    Abiomed (ABMD) Q2 Earnings Top Estimates

    Abiomed (ABMD) delivered earnings and revenue surprises of 10.75% and -0.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Zacks

    Medical Instruments' Oct 31 Earnings Roster: IDXX, ABMD & More

    Earnings and revenues for the Medical Instruments sector in the third quarter are likely to have declined sequentially. Read to know how a few companies from the sector might have fared in the period.

  • Benzinga

    12 Stocks With The Highest Returns On Assets

    There are many ways for fundamental investors to gauge the profitability of a business, and one common method is looking at return on assets. Return on assets is simply a measure of profitability relative ...

  • ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?
    Zacks

    ABIOMED (ABMD) to Report Q2 Earnings: What's in the Offing?

    ABIOMED (ABMD) expects to have gained from its flagship Impella product line in fiscal Q2.

  • Abiomed (ABMD) Earnings Expected to Grow: Should You Buy?
    Zacks

    Abiomed (ABMD) Earnings Expected to Grow: Should You Buy?

    Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Benzinga

    16 Stocks With The Highest Long-Term Sales Growth Rate

    Longtime investors know the stock market is forward-looking. That means a stock’s share price is more a reflection of what investors collectively think the company will do in the future than what it did ...